Woman Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective for this study is to evaluate the safety and tolerability of Herceptin SC in combination with Perjeta IV plus docetaxel in patients with HER2−positive advanced (metastatic or locally recurrent) breast cancer. • Overall safety profile as determined by adverse events of any grade of severity, and adverse events Grade ≥ 3 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0 and cardiac function will be assessed including the following: cardiac events Grade ≥ 3, congestive heart failure (CHF), and cardiac death
Inclusion criteria
- HER2−POSITIVE METASTATIC OR LOCALLY RECURRENT ADVANCED BREAST CANCER